20 March 2020
EMA/CHMP/147656/2020
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Agenda for the meeting on 23-26 March 2020

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

23 March 2020, 09:00 – 18:00, 1C/Adobe Connect

24 March 2020, 08:30 – 18:00, 1C/Adobe Connect

25 March 2020, 08:30 – 18:00, 1C/Adobe Connect

26 March 2020, 08:30 – 16:00, 1C/Adobe Connect

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged.

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 23-26 March 2020. See March 2020 CHMP minutes (to be published post April 2020 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 23-26 March 2020

1.3. Adoption of the minutes

CHMP minutes from the meeting held on 24-27 February 2020.

ORGAM minutes from the meeting held on 17 February 2020.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. indacaterol / glycopyrronium / mometasone - EMEA/H/C/005061

treatment of asthma and to reduce asthma exacerbations

Scope: Oral explanation

Action: Oral explanation to be held on Tuesday, 24 March 2020 at 14:00

List of Outstanding Issues adopted on 30.01.2020. List of Questions adopted on 19.09.2019.

2.1.2. ozanimod - EMEA/H/C/004835

Treatment of multiple sclerosis

Scope: Possible oral explanation

Updated list of experts for the SAG Neurology meeting held on 16.03.2020 was adopted via written procedure on 13.03.2020

SAG report

Action: Possible oral explanation to be held on Tuesday, 24 March 2020 at 11:00

List of Outstanding Issues adopted on 12.12.2019. List of Questions adopted on 25.07.2019.

2.1.3. indacaterol / glycopyrronium / mometasone - EMEA/H/C/005518

treatment of asthma and to reduce asthma exacerbations

Scope: Oral explanation

Action: Oral explanation to be held on Tuesday, 24 March 2020 at 14:00

List of Outstanding Issues adopted on 30.01.2020.

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0070

Takeda Pharma A/S

Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Treatment of adults with previously untreated CD30+ PTCL"

List of experts for SAG Oncology meeting scheduled on 05.03.2020 was adopted via written procedure on 04.03.2020

SAG Report, Oral explanation

Action: Oral explanation to be held on Wednesday, 25 March 2020 at 11:00

Request for Supplementary Information adopted on 30.01.2020, 17.10.2019.

See 5.1

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. indacaterol / mometasone furoate - EMEA/H/C/005067

treatment of asthma

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 30.01.2020. List of Questions adopted on

19.09.2019.

3.1.2. indacaterol / mometasone furoate - EMEA/H/C/005516

treatment of asthma

Scope: Opinion

Action: For adoption

3.1.3. cabazitaxel - EMEA/H/C/005178

treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel-containing regimen

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 27.02.2020. List of Questions adopted on 19.09.2019.

3.1.4. influenza vaccine (surface antigen, inactivated) - Article 28 - EMEA/H/C/004993

Active immunisation against influenza in the elderly (65 years of age and older) and in children 6 months to less than 6 years of age.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 12.12.2019. List of Questions adopted on 25.07.2019.

3.1.5. etanercept - EMEA/H/C/004711

Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Axial spondyloarthritis, Ankylosing spondylitis, Non-radiographic axial spondyloarthritis, Plaque psoriasis, Paediatric plaque psoriasis

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 25.07.2019, 29.05.2019. List of Questions adopted on 20.09.2018.

3.1.6. pretomanid - Orphan - EMEA/H/C/005167

FGK Representative Service GmbH; treatment of tuberculosis

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 30.01.2020. List of Questions adopted on

25.07.2019.

3.1.7. isatuximab - Orphan - EMEA/H/C/004977

sanofi-aventis groupe; For the treatment of patients with multiple myeloma (MM)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 27.02.2020, 12.12.2019. List of Questions adopted on 19.09.2019.

3.1.8. onasemnogene abeparvovec - Orphan - ATMP - EMEA/H/C/004750

AveXis EU Ltd; treatment of spinal muscular atrophy (SMA)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 06.12.2019, 21.06.2019. List of Questions adopted on 22.02.2019.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. aripiprazole - EMEA/H/C/005062

treatment of schizophrenia, or of moderate to severe manic episodes in bipolar I disorder with sensor to measure medication adherence

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.07.2019.

3.2.2. apixaban - EMEA/H/C/005358

prevention of venous thromboembolic events (VTE)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.10.2019.

3.2.3. bevacizumab - EMEA/H/C/005106

treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
First-line treatment of patients with unresectable advanced, metastatic or recurrent non-

small cell lung cancer.
First line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 14.11.2019.

3.2.4. tagraxofusp - Orphan - EMEA/H/C/005031

TMC Pharma (EU) Limited; treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Scope: List of outstanding issues, SAG report from meeting held on 05.03.2020

Action: For adoption

List of Outstanding Issues adopted on 25.06.2019. List of Questions adopted on 24.04.2019.

3.2.5. erlotinib - EMEA/H/C/005071

treatment of lung and pancreatic cancers

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 29.05.2019. List of Questions adopted on 13.12.2018.

3.2.6. fenfluramine - Orphan - EMEA/H/C/003933

Zogenix GmbH; treatment of seizures associated with Dravet syndrome in children aged 2 years to 17 years and adults.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.06.2019.

3.2.7. bulevirtide - Orphan - EMEA/H/C/004854

Accelerated assessment

MYR GmbH; indicated for the treatment of chronic hepatitis delta virus (HDV) infection in adult patients with compensated liver disease.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 28.01.2020.

3.2.8. melphalan - EMEA/H/C/005173

used alone or in combination with other cytotoxic drugs and/or total body irradiation is indicated in the treatment of: multiple myeloma, malignant lymphoma (Hodgkin, non-Hodgkin lymphoma), acute lymphoblastic and myeloblastic leukaemia, childhood neuroblastoma, ovarian adenocarcinoma, mammary adenocarcinoma.
In combination with other cytotoxic drugs and/or total body irradiation, in adult and pediatric population, is indicated as conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (HSCT) in haematological diseases.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.07.2019.

3.2.9. methylthioninium chloride - EMEA/H/C/002776

is indicated as an aid for the enhanced visualization and detection of colorectal lesions in adult patients undergoing screening / surveillance colonoscopy for colorectal cancer.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.06.2019.

3.2.10. obiltoxaximab - Orphan - EMEA/H/C/005169

SFL Regulatory Services GmbH; treatment of inhalational anthrax due to *Bacillus anthracis*

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.10.2019.

3.2.11. doxorubicin - EMEA/H/C/005320

treatment of breast cancer, ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.10.2019.

3.2.12. pexidartinib - Orphan - EMEA/H/C/004832

Daiichi Sankyo Europe GmbH; treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT), also referred to as giant cell tumour of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS)

Scope: List of outstanding issues, SAG report from meeting held on 04.03.2020

Action: For adoption

List of Outstanding Issues adopted on 12.12.2019. List of Questions adopted on 25.07.2019.

3.2.13. lefamulin - EMEA/H/C/005048

treatment of community-acquired pneumonia (CAP)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.10.2019.

3.2.14. lifitegrast - EMEA/H/C/004653

treatment of moderate to severe dry eye disease in adults for whom prior artificial tears has not been sufficient

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 12.12.2019. List of Questions adopted on 26.04.2019.

3.2.15. trastuzumab - EMEA/H/C/005209

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.10.2019.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene - Orphan - ATMP - EMEA/H/C/005321

Accelerated assessment

Orchard Therapeutics (Netherlands) BV; treatment of metachromatic leukodystrophy (MLD)

Scope: List of questions

Action: For information

3.3.2. potassium - Orphan - EMEA/H/C/005407

Advicenne Pharma S.A.; treatment of distal renal tubular acidosis (dRTA) in patients aged 6

months and older.

Scope: List of questions

Action: For adoption

3.3.3. icosapent ethyl - EMEA/H/C/005398

indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Scope: List of questions

Action: For adoption

3.3.4. baloxavir marboxil - EMEA/H/C/004974

Treatment of influenza in patients aged 12 and above, including patients at high risk of developing influenza-related complications and for post-exposure prophylaxis of influenza in individuals aged 12

Scope: List of questions

Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. emapalumab - Orphan - EMEA/H/C/004386

Novimmune B.V.; treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH).

Scope: Letter from the applicant dated 16 March 2020 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in June 2019.

Action: For adoption

List of Outstanding Issues adopted on 27.06.2019. List of Questions adopted on 13.12.2018.

3.4.2. insulin aspart - EMEA/H/C/004965

treatment of diabetes mellitus

Scope: Letter from the applicant dated 17 March 2020 requesting an extension of clock-stop to respond to the list of questions adopted in February 2020.

Action: For adoption

List of Questions adopted on 27.02.2020.

3.4.3. ivosidenib - Orphan - EMEA/H/C/005056

Agios Netherlands B.V.; Treatment of adult patients (≥ 18 years old) with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation

Scope: Letter from the applicant dated 09 March 2020 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in February 2020.

Action: For adoption

List of Outstanding Questions adopted on 27.02.2020. List of Questions adopted on 29.05.2019.

3.4.4. deferiprone - Orphan - EMEA/H/C/005004

Apotex B.V.; treatment of neurodegeneration with brain iron accumulation

Scope: Letter by the applicant dated 10 March 2020 requesting an extension of the clock stop to respond to the list of questions adopted on 19.09.2019

Action: For adoption

List of Questions adopted on 19.09.2019.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. doxorubicin - EMEA/H/C/005194

treatment of breast cancer, ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma

Scope: Withdrawal of initial marketing authorisation application

Action: For information

List of Outstanding Issues adopted on 27.02.2020, 12.12.2019. List of Questions adopted on 19.09.2019.

3.7.2. rituximab - EMEA/H/C/005387

treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL)

Scope: Withdrawal of initial marketing authorisation application

Action: For information

Oral explanation held on 27.02.2020. List of Outstanding Issues adopted on 12.12.2019, 27.06.2019.

3.7.3. rituximab - EMEA/H/C/004807

treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL) and Rheumatoid arthritis

Scope: Withdrawal of initial marketing authorisation application

Action: For information

Oral explanation held on 27.02.2020. List of Outstanding Issues adopted on 12.12.2019, 27.06.2019. List of Questions adopted on 18.10.2018.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Jorveza - budesonide - Orphan - EMEA/H/C/004655/X/0007/G

Dr. Falk Pharma GmbH

Rapporteur: Martina Weise, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Zane Neikena

Scope: "Extension application to add a new strength of 0.5 mg for budesonide orodispersible tablets, grouped with:
- A type II variation (C.I.6) - Extension of indication to include the maintenance of remission for Jorveza (0.5 mg and 1 mg orodispersible tablets); as a consequence, sections 4.2, 4.8 and 5.1 of the SmPC are updated to reflect the recommended daily dose and duration of treatment of Jorveza for the maintenance of remission, to update the list of adverse reactions and the clinical efficacy and safety information based on the results of the phase III clinical study BUL-2/EER. The relevant sections of the PL are updated accordingly. In addition, a revised RMP (version 2.0) has been submitted to reflect the results of this study and to align with the GVP Module V (rev 2) template. The MAH also took the opportunity to bring the product information in line with the latest QRD template (version 10.1).
- A type IB variation (B.II.e.5.a.2)"

Action: For adoption

List of Questions adopted on 12.12.2019.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Darzalex - daratumumab - Orphan - EMEA/H/C/004077/X/0032

Janssen-Cilag International NV

Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection), a new strength (1800 mg) and a new route of administration (subcutaneous route). The RMP version 7.0 was updated in accordance."

Action: For adoption

List of Questions adopted on 12.12.2019.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/X/0083/G

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension application to add a new strength of 75 mg film-coated tablets of ivacaftor to enable administration to patients aged 6 to less than 11 years.
C.II.6.a - To update sections 4.1, 4.2 and 6.5 the SmPC, and sections 1 and 2 of the PL for the 150 mg film-coated tablet presentations to extend the indication for use in children aged 6 to less than 11 years old in combination with tezacaftor/ivacaftor and to bring it in line with the new dosage form (75 mg film-coated tablets of ivacaftor). The RMP (version 8.6) is updated in accordance. In addition, the MAH took the opportunity to implement minor updates in the Product Information."

Action: For adoption

4.3.2. Lacosamide Accord - lacosamide - EMEA/H/C/004443/X/0007

Accord Healthcare S.L.U.

Rapporteur: John Joseph Borg, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce a new pharmaceutical form (solution for infusion), a new strength (10mg/ml) and a new route of administration (intravenous use)."

Action: For adoption

4.3.3. Praluent - alirocumab - EMEA/H/C/003882/X/0054/G

sanofi-aventis groupe

Rapporteur: Johann Lodewijk Hillege

Scope: "Grouping of:
• Extension application to introduce a new strength of 300 mg solution for injection in pre-filled pen (in a pack of 1 and 3 pens, EU/1/15/1031/019-20)
• B.II.b.3.z
• B.II.d.2.a
• B.II.e.5.a.1
• B.II.e.5.a.1
• B.II.e.5.a.1
• B.II.e.5.a.1
• B.II.e.5.a.1
• B.II.e.6.b
• B.IV.1.c
Update of sections 1, 2, 4.2, 6.3, 6.5 and 8 of the SmPC; the Labelling and Package Leaflet are updated accordingly.
In addition, the applicant has taken the opportunity to update the contact details of the Maltese local representative in the Package Leaflet, to bring the PI in line with the latest QRD template (v. 10.1) and to introduce editorial changes."

Action: For adoption

4.3.4. Symkevi - tezacaftor / ivacaftor - Orphan - EMEA/H/C/004682/X/0015/G

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension application to add a new strength of 50/75 mg film-coated tablets of tezacaftor/ivacaftor to enable administration to patients aged 6 to less than 11 years.
C.II.6.a - To update sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.1 of the SmPC, and sections 2, 3 and 6 of the PL for the 100/150 mg film-coated tablet presentations to extend the indication for use in children aged 6 to less than 11 years old in combination with ivacaftor and to bring it in line with the new dosage form (50/75mg film-coated tablets tezacaftor/ivacaftor). The RMP (version 2.1) is updated in accordance.
In addition, the MAH took the opportunity to implement minor updates and formatting changes in the Product Information."

Action: For adoption

4.3.5. Tepadina - thiotepa - Orphan - EMEA/H/C/001046/X/0036

ADIENNE S.r.l.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (400 mg powder and solvent for solution for infusion)."

Action: For adoption

4.3.6. Trimbow - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004257/X/0008/G

Chiesi Farmaceutici S.p.A.

Rapporteur: Janet Koenig, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension application to introduce a new strength (172 µg / 5 µg / 9 µg) grouped with a type II variation (C.I.6.a) to add a new indication (asthma). The RMP (version 6.1) is updated in accordance." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

4.3.7. Trulicity - dulaglutide - EMEA/H/C/002825/X/0045

Eli Lilly Nederland B.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Ilaria Baldelli

Scope: "Extension application to introduce two new strengths of 3 mg and 4.5 mg solution for injection."

Action: For adoption

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0070

Takeda Pharma A/S

Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Treatment of adults with previously untreated CD30+ PTCL"

List of experts for SAG Oncology meeting scheduled on 05 March 2020 was adopted via written procedure on 04 March 2020

SAG Report, Oral explanation

Action: For adoption

Request for Supplementary Information adopted on 30.01.2020, 17.10.2019.

See 2.3

5.1.2. Cosentyx - secukinumab - EMEA/H/C/003729/II/0053/G

Novartis Europharm Limited

Rapporteur: Tuomo Lapveteläinen, PRAC Rapporteur: Eva A. Segovia

Scope: "Grouping of two variations:
One type II variation II C.I.6.a: Extension of indication to include the treatment of Non-radiographic axial spondyloarthritis (nr-axSpA) / axial spondyloarthritis (axSpA) without radiographic evidence for Cosentyx. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 of the SmPC are amended. The package leaflet is amended in accordance. The updated RMP version 5.0 has also been submitted.
One type IB C.I.11.z to change the due date of the Psoriasis Registry (category 3 study) within the RMP."

Action: For adoption

Request for Supplementary Information adopted on 12.12.2019.

5.1.3. Intelence - etravirine - EMEA/H/C/000900/II/0058

Janssen-Cilag International NV

Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Adrien Inoubli

Scope: "To extend the approved therapeutic indication of Intelence in order to include patient population from 2 to 6 years of age based on the 48 week study results from study TMC125-C234/P1090 (A Phase I/II, Open-label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-experienced HIV-1 Infected Infants and Children, Aged ≥2 Months to <6 Years). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and sections 1, 2 and 3 of the PL are updated accordingly. The updated RMP version 13.1 has also been submitted. The RMP (version 13.1) of the product has been updated to remove the completed additional pharmacovigilance activities (TMC125-C234/P1090 (Week 48) and TMC125-EPPICC) from the pharmacovigilance plan of the RMP). The RMP has also been updated to meet the requirements and updated definitions in the European Medicines Agency (EMA) Guideline on good pharmacovigilance practices (GVP) Module V Revision 2 (EMA/838713/2011; Rev 2) and Guidance on the format of the RMP in the European Union (EMA/164014/2018 Rev 2.0.1) including proposed removal of safety concerns.
The MAH took the opportunity to include some typographic changes in Annex II C and D."

Action: For adoption

Request for Supplementary Information adopted on 30.01.2020.

5.1.4. Kineret - anakinra - EMEA/H/C/000363/II/0070

Swedish Orphan Biovitrum AB (publ)

Rapporteur: Mark Ainsworth, Co-Rapporteur: Fátima Ventura, PRAC Rapporteur: Hans Christian Siersted

Scope: "Extension of indication to include the treatment of Familial Mediterranean Fever (FMF) for Kineret, to be given in combination with colchicine, if appropriate; as a consequence, sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 5.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 30.01.2020.

5.1.5. Latuda - lurasidone - EMEA/H/C/002713/II/0029

Aziende Chimiche Riunite Angelini Francesco S.p.A.

Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication for the treatment of schizophrenia in adolescent from 13 to less than 18 years. As a consequence, sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) takes the opportunity to update the PI according to the excipient guideline and update the list of local representatives in the Package Leaflet. The RMP version 8 has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

5.1.6. Lynparza - olaparib - EMEA/H/C/003726/II/0035

AstraZeneca AB

Rapporteur: Alexandre Moreau, Co-Rapporteur: Koenraad Norga, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include the use of Lynparza tablets in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy with bevacizumab. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC are updated. The PL is updated accordingly. In addition, sections 4.4 and 4.8 of the SmPC for Lynparza hard capsules are revised based on updated safety data analysis. Furthermore, the PI is brought in line with the latest QRD template version 10.1. The RMP version 19 has also been submitted."

Action: For adoption

5.1.7. Lynparza - olaparib - EMEA/H/C/003726/II/0036

AstraZeneca AB

Rapporteur: Alexandre Moreau, Co-Rapporteur: Koenraad Norga, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include the use of Lynparza tablets as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene mutations (germline and/or somatic) who have progressed following a prior new hormonal agent. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 of the SmPC are updated. The PL is updated accordingly. In addition, sections 4.4 and 4.8 of the SmPC for Lynparza hard capsules are revised based on updated safety data analysis. The RMP version 20 has also been submitted."

Action: For adoption

5.1.8. Ofev - nintedanib - Orphan - EMEA/H/C/003821/II/0027

Boehringer Ingelheim International GmbH

Rapporteur: Peter Kiely, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include new indication for OFEV for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype based on the results of pharmacology studies and the double-blind, randomised, placebo-controlled phase III trial (INBUILD). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to reflect the use of Ofev in the new indication. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce minor formatting changes in the PI. Furthermore, the PI is brought in line with the latest QRD template version 10.1. The RMP version 9.0 has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 12.12.2019.

5.1.9. Olumiant - baricitinib - EMEA/H/C/004085/II/0016

Eli Lilly Nederland B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Bart Van der Schueren, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include a new indication in the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy for Olumiant; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Minor editorial changes were brought to the Labelling. Furthermore, the Annex II is brought in line with the latest QRD template version 10.1. The RMP version 8.1 has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

5.1.10. Ruconest - conestat alfa - EMEA/H/C/001223/II/0053/G

Pharming Group N.V

Rapporteur: Andrea Laslop, PRAC Rapporteur: Jan Neuhauser

Scope: "Update of indication to include children in the treatment of acute angioedema attacks with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. This is based from Study C1 1209 in children. In addition final efficacy and safety data from the OLE phases of Studies C1 1304 and 1205 and the completed Study C1 1310 are submitted together with final study results of Studies C1 1207 and 3201, concerning prophylactic treatment of HAE patients. Consequently the product information has been updated. Furthermore, the company is requesting an extension for the completion of registry Study C1 1412. The current RMP (V 18.0) states that completion of the final study report for Study C1 1412 is anticipated 31 March 2020. Although patient enrolment has increased, the study will not be completed on time. The MAH would therefore like to request an extension of the study completion date to submit the final report date for Study C1 1412 of 30 June 2022. In addition, as mentioned below, the RMP has also been aligned to RMP template version 2.0.1.
The product information has also been updated to align with the most recent QRD template, version 10.1."

Action: For adoption

Request for Supplementary Information adopted on 30.01.2020.

5.1.11. Taltz - ixekizumab - EMEA/H/C/003943/II/0030

Eli Lilly Nederland B.V.

Rapporteur: Kristina Dunder, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adult patients with active axial spondyloarthritis; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC and relevant section of the PL are updated. The PI was also brought in line with the latest QRD template version 10.1. In addition, an updated RMP version 6.1 has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 12.12.2019.

5.1.12. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0033

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1 for Tecentriq based on the results of the pivotal study GO29431 (IMpower110), comparing atezolizumab monotherapy to platinum-based chemotherapy. As a consequence, sections 4.1, 4.2, 4.8

and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. The RMP version 12.0 has also been submitted."

Action: For adoption

5.1.13. Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0013

Pfizer Europe MA EEIG

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Extension of indication for Trumenba to include active immunisation of children 1-9 years old. Sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated in parallel based on the results from the two pivotal studies B1971017 and B1971035. The Package Leaflet is updated in accordance. The RMP version 2.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to submit a corrected version of the final report of study B1971016, which was included in the initial marketing authorisation application."

Action: For adoption

Request for Supplementary Information adopted on 14.11.2019, 25.07.2019, 28.02.2019.

5.1.14. Ultomiris - ravulizumab - EMEA/H/C/004954/II/0002

Alexion Europe SAS

Rapporteur: Jorge Camarero Jiménez, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include the treatment of patients with atypical hemolytic uremic syndrome (aHUS) for Ultomiris; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, Annex II.D is proposed to be updated to include the risk of thrombotic microangiopathy (TMA) with the new indication in the educational materials. The RMP version 1.6 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 14.11.2019.

5.1.15. Zavicefta - ceftazidime / avibactam - EMEA/H/C/004027/II/0015

Pfizer Ireland Pharmaceuticals

Rapporteur: Bjorg Bolstad, Co-Rapporteur: Simona Stankeviciute, PRAC Rapporteur: Rugile Pilviniene

Scope: "Extension of indication to include paediatric patients aged 3 months to less than 18 years for Zavicefta (for the treatment of cIAI and cUTI), based on data from paediatric studies D4280C00014, C3591004 and C3591005 and the population PK modelling/simulation analyses (CAZ-MS-PED-01 and CAZ-MS-PED-02).
As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2, 6.3 and 6.6 of the SmPC are updated in order to reflect this additional population, the paediatric posology, paediatric safety

information, the description of the clinical trials and handling instructions for paediatric dosing. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to correct the sodium content to SmPC sections 2 and 4.4 and PL section 2 and the volumes of distribution of ceftazidime and avibactam in SmPC section 5.2. Furthermore, the MAH is also introducing a correction in the Czech SmPC to add missing values in the table in SmPC section 5.1. The RMP version 3.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.07.2019.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Xtandi - enzalutamide - EMEA/H/C/002639/II/0047/G

Astellas Pharma Europe B.V.

Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Eva A. Segovia

Scope: "C.1.6: Extension of indication to include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) for Xtandi in combination with androgen deprivation therapy; As a consequence, sections 4.1, 4.7, 4.8, 5.1, 5.3 and 6.6 of the SmPC are updated. Furthermore the MAH took the opportunity to make corrections to section 4.7. The Package Leaflet is updated in accordance. The RMP version 13.0 has also been submitted.
C.1.4: Update of section 5.1 of the SmPC based the 5-year Overall Survival (OS) results obtained from the PREVAIL study (MDV310003), a phase 3 study of enzalutamide in chemotherapy naïve patients with metastatic prostate cancer that progressed on ADT."

revised timetable

Action: For discussion

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. idecabtagene vicleucel - H0004662

Treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

8.1.2. trastuzumab deruxtecan - H0005124

Treatment of HER2-positive breast cancer and HER2-positive gastric cancer. DS-8201a as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 therapies

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

8.2. Priority Medicines (PRIME)

Disclosure of information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Desloratadine ratiopharm - desloratadine - EMEA/H/C/002404/II/0023/G

ratiopharm GmbH

Rapporteur: Koenraad Norga, Co-Rapp: Peter Kiely, PRAC Rapporteur: Jean-Michel Dogné

Scope: "C.I.5.b - Change in the legal status of desloratadine ratiopharm from 'medicinal product subject to medical prescription' to 'medicinal product not subject to medical prescription' in view of the safety profile of desloratadine ratiopharm and the post-marketing experience already available with other medicinal products containing similar long acting histamine antagonists. The RMP version 1.0 has also been submitted. In addition, the MAH also took the opportunity to bring the PI in line with the latest QRD template (version 10.1), to update the list of local representatives in the package leaflet and to make editorial changes.
C.I.6.b - To delete the therapeutic indication in adolescents aged 12 years and older for the relief of symptoms associated with allergic rhinitis and urticaria. Section 4.1 of the SmPC and section 1 of the PL are updated accordingly."

Action: For discussion

9.1.2. Fortacin - lidocaine / prilocaine - EMEA/H/C/002693/II/0030

Recordati Ireland Ltd

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Change in the legal status of Fortacin from 'medicinal product subject to medical prescription' to 'medicinal product not subject to medical prescription' in view of the safety profile of Fortacin, the post-marketing experience already available with other medicinal products containing amide local anaesthetics and in view of making the product more accessible to the target population. Furthermore, the PI is being brought in line with the latest QRD template (version 10.1). The RMP version 3.1 has also been submitted."

Action: For discussion

Request for Supplementary Information adopted on 12.12.2019.

9.1.3. Kanuma - sebelipase alfa - EMEA/H/C/004004/II/0026/G, Orphan

Alexion Europe SAS

Rapporteur: Bart Van der Schueren, Co-Rapporteur: Fátima Ventura

Scope: Grouped variations consisting of
1) update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the clinical information based on the pooled safety and efficacy analysis of already submitted studies (namely study LAL-CL04: an open label multicentre extension study to evaluate the long-term safety, tolerability, and efficacy of sebelipase alfa (SBC-102) in adult subjects with liver dysfunction due to lysosomal acid lipase deficiency (LAL-D) who previously received treatment in study LAL-CL01; study LAL-CL03: an open label, multicentre, dose escalation study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of SBC-102 in children with growth failure due to LAL-D; study LAL-CL06: a multicentre, open-label study of sebelipase alfa in patients with LAL-D; study LAL-CL08: a phase 2, open label, multicentre study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of sebelipase alfa in infants with rapidly progressive LAL-D; study LAL-CL02: a multicentre, randomized, placebo-controlled study of SBC-102 in patients with LAL-D) and updated population pharmacokinetic (PK) analyses in children and adults. The package leaflet and the RMP (version 4.0) are updated accordingly. Annex II is also updated to remove the obligation related to the provision of study LAL-CL08;
2) submission of the final report from study LAL-EA01: an open-label study with sebelipase alfa 1 mg/kg every other week for up to 78 weeks or until drug commercialisation in the United States (US) patients who did not otherwise qualify for an active sebelipase alfa trial (expanded access protocol)

Action: For adoption

9.1.4. Lokelma - sodium zirconium cyclosilicate - EMEA/H/C/004029/II/0013

AstraZeneca AB

Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Kirsti Villikka

Scope: "Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to update the clinical information based final results from study DIALIZE. This was a Phase 3b, multicentre, prospective, randomised, double-blind, placebo-controlled study to reduce incidence of pre-dialysis hyperkalaemia with sodium zirconium cyclosilicate. The Package Leaflet and Labelling are updated accordingly. The RMP version 2.1 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement the new excipient statement for sodium in section 4.4 of the SmPC, section 2 of Labelling and section 2 of the Package Leaflet. Furthermore, minor editorial changes were introduced in section 2 of the Package leaflet."

Action: For discussion

Request for Supplementary Information adopted on 12.12.2019, 19.09.2019.

9.1.5. PD1/PD-L1 targeting agents

Scope: LEG procedure, Response from the Biostatistics Working Party

Action: For discussion

9.1.6. Tyverb - lapatinib - EMEA/H/C/000795/II/0059

Novartis Europharm Limited

Rapporteur: Filip Josephson

Scope: "Update of section 5.1 of the SmPC in order to update Table 8 based on updated/corrected results from study EGF114299/LAP016A2307, an interventional study with progression free survival rate as primary objective, original report submitted during procedure EMEA/H/C/00795/II/0051."

Action: For adoption

Request for Supplementary Information adopted on 14.11.2019, 26.04.2019.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Direct Oral Anticoagulants (DOAC) - EMEA/H/A-5(3)/1478

MAHs: various

Referral Rapporteur: Martina Weise, Referral Co-Rapporteurs: Kristina Dunder

Rapporteurs for involved CAPs:

Eliquis (APIXABAN):
Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Bart van der Schueren;

Pradaxa (DABIGATRAN ETEXILATE):
Rapporteur: Mark Ainsworth, Co-Rapporteur: Jean-Michel Race;

Xarelto (RIVAROXABAN):
Rapporteur: Kristina Dunder, Co-Rapporteur: Martina Weise

Scope: Opinion

Action: For adoption

10.2.2. Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients EMEA/H/A-5(3)/1490

MAHs: various

Referral Rapporteur: Martina Weise, Referral Co-Rapporteurs: Kristina Dunder

Scope: Report from the ad-hoc expert group meeting scheduled on 27-28 February 2020,

QWP, SWP, PRAC and BWP responses to CHMP lists of questions

Action: For discussion

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Budesonide SUN – budesonide – EMEA/H/A-29(4)/1492

MAH: Sun Pharmaceutical Industries Europe B.V.

Referral Rapporteur: Johann Lodewijk Hillege, Referral Co-Rapporteur: Giuseppa Pistritto

Scope: Opinion

Action: For adoption

The applicant has submitted an Art. 10(3) application for Budesonide SUN nebuliser suspension and associated names. Concerns regarding the demonstration of bioequivalence have been raised by IT and UK who were of the view that the data presented (comparative in vitro data of the product before nebulisation, including Particle Size Distribution (PSD) of the active substance) are not sufficient to demonstrate bioequivalence. The procedure was initiated because of disagreements regarding which in-vitro data are considered pivotal.

10.4.2. Carbamazepine – EMEA/H/A-29(4)/1497

MAH: Laboratorios Tillomed Spain S.L.U

Referral Rapporteur: TBC, Referral Co-Rapporteur: TBC

Scope: Start of procedure, timetable, appointment of Rapporteurs

Action: For adoption

Summary: Disagreements regarding the bioequivalence acceptance criteria for Cmax of carbamazepine. The objecting MS is of the opinion that bioequivalence has not been demonstrated between the test and the reference product.

10.4.3. Ibuprofen Kabi – EMEA/H/A-29(4)/1498

MAH: Fresenius Kabi Deutschland GmbH

Referral Rapporteur: TBC, Referral Co-Rapporteur: TBC

Scope: Start of procedure, list of Questions, timetable, appointment of Rapporteurs

Action: For adoption

Summary: Decentralised Procedure number: DE/H/6040/001/DC, notification by the German Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC.

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. Fosfomycin-containing medicinal products – EMEA/H/A-31/1476

MAHs: various

Referral Rapporteur: Ondrej Slanar, Referral Co-Rapporteur: Janet Koenig

Scope: Opinion

Action: For adoption

Need to re-evaluate the benefit-risk ratio of the approved indications considering the current scientific knowledge. Furthermore, the appropriate dose and duration of administration for both oral and intravenous formulations need to be discussed as well as the adequacy of safety relevant information and information about pharmacological properties.

The German National Competent Authority triggered a referral under Article 31 of Directive 2001/83 based on interest of the Union, requesting an opinion to CHMP on the benefit-risk of fosfomycin-containing products and on the need for regulatory measures to be taken.

10.6.2. Gadolinium-containing contrast agents (GdCA): Gadobutrol (NAP); gadodiamide (NAP); gadopentetic acid (NAP); gadoteric acid (NAP); gadoteridol (NAP); gadoxetic acid (NAP) - EMEA/H/A-31/1097; Optimark (withdrawn) – gadoversetamide - EMEA/H/C/000745/ANX/014.12

Applicant: various

Referral Rapporteur: Johann Lodewijk Hillege

Scope: Final analysis report of long-term effects Study ALS-Gd64/001 (“Bone study”) on gadolinium accumulation in the bone for gadoversetamide, gadoteric acid, gadobutrol, gadoxetic acid, gadopentetic acid and gadodiamide containing medicinal products.

Timetable

Action: For adoption

10.6.3. Methocarbamol/Paracetamol– EMEA/H/A-31/1484

MAHs: FAES FARMA, S.A., DiaMed Beratungsgesellschaft fuer pharmazeutische Unternehmen mbH

Referral Rapporteur: Romaldas Maciulaitis, Referral Co-Rapporteur: Jorge Camarero Jimenez

Scope: Opinion

Action: For adoption

Review of the benefit-risk balance following notification by BfArM in Germany on 27 May 2019 of a referral under Article 31 of Directive 2001/83/EC.

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

March 2020 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

Action: For information

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Rules of procedures

Amendments to the existing Rules of procedures of EMA's scientific committees

Action: For adoption

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 09-12 March 2020

Action: For information

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for March 2020

Action: For adoption

14.2.2. Committee for Advanced Therapies (CAT)

CAT draft minutes of meeting held on 18-20 March 2020

Action: For information

14.2.3. Committee for Herbal Medicinal Products (HMPC)

Report from the HMPC meeting held on 02-04 March 2020

Action: For information

14.2.4. Paediatric Committee (PDCO)

PIPs reaching D30 at March 2020 PDCO

Action: For information

Report from the PDCO meeting held on 24-27 March 2020

Action: For information

14.2.5. Committee for Orphan Medicinal Products (COMP)

Report from the COMP meeting held on 17-19 March 2020

Action: For information

14.2.6. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh)

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 24-26 March 2020

Action: For information

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Ad-hoc Influenza Working Group

Scope EU Strain selection for the Influenza Vaccines for the Season 2020/2021: Report from the Ad Hoc Influenza working group to the BWP

Action: For adoption

Postponed from February.

Scope: EU Recommendation for the Seasonal Influenza Vaccine Composition for the Season 2020/2021

Action: For adoption

14.3.2. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP March 2020 meeting to CHMP for adoption:

- 10 reports on products in scientific advice and protocol assistance
- 7 reports on products in pre-authorisation procedures
- 1 report on products in plasma master file

Action: For adoption

14.3.3. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 25-26 March 2020.

Action: For adoption

14.3.4. Pharmacokinetics Working Party (PKWP)

Chair: Henrike Potthast

Election of PKWP vice chair

Previous vice chair Henrike Potthast has now become the chair of PKWP.

Action: For election

14.3.5. Quality Working Party (QWP)

Chair: Blanka Hirschlerova

Election of new QWP vice chair

Previous vice chair Blanka Hirschlerova has now become the chair of QWP.

Action: For election

14.3.6. Safety Working Party (SWP)

Chair: Jan Willem Van der Laan

CMDh question to SWP - Determination of acceptable intake levels of chlorobutanol as excipient

Action: For adoption

14.3.7. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 09-12 March 2020. Table of conclusions

Action: For information

Scientific advice letters:

Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

14.8.1. Update of the Business Pipeline report for the human scientific committees

2020 initial marketing authorisation application submissions with eligibility request to central procedure

Action: For information

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

16. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths,

formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a

particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/